

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 2

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>MB</i>	Nair N.P.V., Schwartz G., Dimitri R. et al. A dose-range finding study of zopiclone in insomniac patients. <i>Intl Clin Psychopharmacol</i> 1990; 5 (Suppl 2): 1-10.
<i>MB</i>	Martindale. The Extra Pharmacopoeia. The Royal Pharmaceutical Society, London 1996; 31 st edition: pp. 743-744.
<i>MB</i>	Houghton G.W., Dennis M.J., Templeton R., Martin B.K.. A repeated dose pharmacokinetic study of a new hypnotic agent, zopiclone (Imovane®). <i>Intl J Clin Pharmacol Therap Toxicol</i> 1985; 23: 97-100
<i>MB</i>	Marc-Aurèle J., Caille G., Bourgoïn J. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effects of hemodialysis. <i>Sleep</i> 1987; 10 (Suppl 1): 22-26
<i>MB</i>	Parker G., Roberts C.J.C.. Plasmas concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease. <i>Br J Clin Pharmacol</i> 1983; 16:259-265.
<i>MB</i>	Viron B., De Meyer M., Le Liboux A. et al., Steady-state pharmacokinetic of zopiclone during multiple oral dosing (7.5 mg nocte) in patients with severe chronic renal failure. <i>Intl Clin Pysychopharmacol</i> 1990; 5 (Suppl 2): 95-104.
<i>MB</i>	Sikdar S., Ruben S.M., Zopiclone abuse among polydrug users. <i>Addiction</i> 1996; 91: 285-286.

Examiner <i>Mark Ba</i>	Date Considered <i>7/6/01</i>
-------------------------	-------------------------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUN 11 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 3

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<i>MB</i>	Noble S., Langtry H.D., Lamb H.M., Zopiclone. An update of its pharmacology, clinical efficacy and tolerability in the treatment of insomnia. <i>Drugs</i> 198; 55:277-302.
<i>MB</i>	Fernandez C., Martin C., Gimenez F., Farinotti. Clinical pharmacokinetics of zopiclone, <i>Clin Pharmacokinet</i> 1995; 29: 431-441.
<i>MB</i>	Le Liboux Z., Frydman A., Gaillot J., Simultaneous Determination of Zopiclone and Its Two Major Metabolites (N-Oxide and N-Desmethyl) in Human Biological Fluids by Reversed-Phase High-Performance Liquid Chromatography, <i>J. Chromatography</i> , 417: (1987) 151-158.
<i>MB</i>	Musch B. and Maillard F., Zopiclone, The Third Generation Hypnotic: a Clinical Overview, <i>Intl. Clin. Psychopharmacol.</i> 5: 147-58 (1990)
<i>MB</i>	Julou L., Blanchard J.C., and Dreyfus J.F., Pharmacological and Clinical Studies of Cyclopyrrolones: Zopiclone and Suriclone, <i>Pharmacol., Biochem. & Beh.</i> , 23: 653-659 (1985).
<i>MB</i>	Broadhurst A. and Cushnaghan R.C., Residual effects of Zopiclone (Imovane), <i>Sleep</i> , 10 (Suppl. 1): 48-53 (1987).
<i>MB</i>	Anderson A., Zopiclone and Nitrazepam: A Multicenter Placebo Controlled Comparative Study of Efficacy and Tolerance in Insomniac Patients in General Practice, <i>Sleep</i> , 10 (Suppl. 1): 54-62 (1987).
<i>MB</i>	Tamminen T. and Hensen P.P., Chronic Administration of Zopiclone and Nitrazepam in the Treatment of Insomnia, <i>Sleep</i> , 10 (Suppl. 1): 63-72 (1987).

Examiner

Mark LBN

Date Considered

7/6/01

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

JUN 11 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 4

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
NB	5,786,357	7/28/98	Young et al.	514	249	12/1/92

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NB	Inman W., Kubota K., Pearce G., Wilton W., PEM Report Number 10. Zopiclone, <i>Pharmacoepidemiol Drug Safety</i> 1993; 2: 499-521.
NB	Doble A., Canton T., Malgouris C., et al. The mechanism of action of zopiclone. <i>Eur Psychiat</i> 1995; 10 (Suppl 3): 117s-128s.
NB	Karle J. and Nielsen M., The Mechanism of Action and Pharmacology of Zopiclone, Rev. <i>Contemp. Pharmacother.</i> , Vol. 9, No. 2, pp. 77-87 (1998).
NB	Richards G., Schoch P., Haefely W., Benzodiazepine receptors: new vistas. <i>Sem Neurosci</i> 1991; 3: 191-203.
NB	Doble A., Martin I.L., <u>The GABA_A benzodiazepine receptor as a target for psychoactive drugs.</u> RG Landes Company, Austin 1996; pp. 229-264.
NB	Langtry H.D., Benfield P., Zolpidem: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential, <i>Drugs</i> , 1990; 40: 291-313.
NB	Blanchard J.C., Boireau A., Garret C., Julou L. <u>In vitro and in vivo inhibition by zopiclone of benzodiazepine binding to rodent brain receptors.</u> <i>Life Sci</i> 1979; 24: 2417-2420.
NB	Möhler H., Okada T. The benzodiazepine receptor in normal and pathological human brain. <i>Brit J Psychiat</i> 1978; 133: 261-268.
NB	Gaillot J., Le Roux Y., Houghton G.W., Dreyfus J.F.. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. <i>Sleep</i> 1987; 10 (Suppl 1): 7-21.

Examiner	<i>Mark Bm</i>	Date Considered	<i>7/6/01</i>
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 5

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
MB	3,862,149	01/21/75	Cotrel et al.	260	2683Q	
MB	4,220,646	09/02/80	Cotrel et al.	424	250	
MB	5,786,357	07/28/98	Young et al.	514	219	

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub Class	Trans. Yes	Trans. No
MB	EP 0 495 717	07/22/92	Europe				
MB	WO 93/10788	06/10/93	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB	Doble et al., "The Pharmacology of Cyclopymrolone Derivatives Acting at the GABA _A /Benzodiazepine Receptor," <i>Adv. Biochem. Psychopharmacol.</i> , 47:407-418 (1992).
MB	Gaillot et al., "Pharmacokinetics and Metabolism of Zopiclone," <i>Int. Pharmacophysiol.</i> 17:suppl. 2, pp. 76-91 (1982)/ <i>Pharmacology</i> 27:suppl. 2, pp. 76-91 (1983).
MB	E.J. Ariens, "Stereoselectivity in Pharmacodynamics and Pharmacokinetics," <i>Schweiz. Med. Wschr.</i> 120:131-134 (1990).
MB	Dragstedt, C.A. and Lang, V.F., "Respiratory Stimulants in Acute Cocaine Poisoning in Rabbits," <i>J. Pharmacol. Ex. Ther.</i> 32:215-222 (1928).
MB	Litchfield, J.T., Jr., and Wilcoxon, F., "A Simplified Method of Evaluating Dose-Effect Experiments," <i>J. Pharmacol. and Exp. Therap.</i> 96:99-113 (1949).
MB	Casarett and Doull's Toxicology: The Basic Science of Poisons, 5th ed. (1996) pp. 21-23.
MB	Prieur, David J. et al., "Procedures for Preclinical Toxicologic Evaluation of Cancer Chemotherapeutic Agents: Protocols of the Laboratory of Toxicology," <i>Cancer Chemotherapy Reports</i> , January 1973, part 3, vol. 4, no. 1:1-30.
MB	Everett et al., "Comparative Anticonvulsive Action of 3,5,5-Trimethyloxazolidine-2,4-Dione (Tridone), Dilantin and Phenobarbital," <i>J. Pharmacol.</i> 81:402 (1944).

Examiner	<i>Mark Ben</i>	Date Considered	<i>7/6/01</i>
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>			

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 6

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
MB	4,962,124	10/09/90	Sunshine et al.	514	568	
MB	5,102,890	04/07/92	Bourzat et al.	514	295	

FOREIGN PATENT DOCUMENTS


Examiner Initial	Document Number	Date	Country	Class	Sub Class	Trans. Yes	Trans. No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.):

MB		Schwinn et al., "Functional Effects of Activation of Alpha-1 Adrenoceptors by Dexmedetomidine: In Vivo and In Vitro Studies," <i>J. Pharmacol. & Exp. Therap.</i> , 259 (1991).
MB		Marley et al., "Differential Response to Flurazepam in Long-Sleep and Short-Sleep Mice," <i>Pharmacol. Biochem. & Behav.</i> , 31:453-58 (1987).
MB		G. Zbinden et al., "Pharmacology of Benzodiazepines: Laboratory and Clinical Correlations," <i>Advances in Pharmacology</i> , 5:213-291 (1967).
MB		W.H. DeCamp, "The FDA Perspective on the Development of Stereoisomers," <i>Chirality</i> , 1:2-6 (1989).
MB		D.J. Birkett, "Racemates or Enantiomers: Regulatory Approaches," <i>Clinical and Experimental Pharmacology & Physiology</i> , 16:479-483 (1989).
MB		R.F. Squires et al., "Benzodiazepine Receptors in Rat Brain," <i>Nature</i> , 266:732-734 (1977).
MB		R.E. Study et al., "Cellular Mechanisms of Benzodiazepine Action," <i>JAMA</i> , 247:2147-2151 (1982).
MB		D. Nutt, "Selective Ligands for Benzodiazepine Receptors: Recent Developments," <i>Curr. Aspects Neurosci.</i> , 2:259-293 (1990).

Examiner	<i>Mark Burt</i>	Date Considered	<i>7/6/01</i>
----------	------------------	-----------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



Page 7

Ap
Fili

OIPE
JUN 07 2001
PATENT & TRADEMARK OFFICE

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date
MB	5,331,000	07/19/94	Young et al.	514	570	

Examiner Initial	Document Number	Date	Country	Class	Sub Class	Trans. Yes	Trans. No

OTHER DOCUMENTS (including Patent, Title, Date, Volume, Page, etc.)		
MB		G. Richards et al., "Role of GABA in the mechanism of benzodiazepine action," <i>Seminars in Neurosciences</i> , 3:191-203 (1991).
MB		J.T. Litchfield, "A Method for Rapid Graphic Solution of Time-Percent Effect Curves," <i>J. Pharmacol. and Exp. Therap.</i> , 97:399-408 (1949).
MB		G.W. Snedecor et al., <i>Statistical Methods</i> , 7th ed., 149.
MB		Fiche Technique No. 6, <i>J. Pharmacol. and Experim. Therap.</i> , 3:407-914 (1970).
MB		E.J. Ariens, "Racemic Therapeutics - ethical and regulatory aspects," <i>Eur. J. Clin. Pharmacol.</i> 41:89-93 (1991).
MB		C. Fernandez et al., "Determination of zopiclone enantiomers in plasma by liquid chromatography using a chiral cellulose carbonate column," <i>J. Chromatog.</i> , 572:195-202 (1991).
MB		P. Gauthier et al., "Influence of Zopiclone, a New Generation Hypnotic, on the Intermediate Stage and Paradoxical Sleep in the Rat," <i>Psychopharmacol.</i> , 130:139-143 (1997).
MB		Goodman & Gilman's, <i>The Pharmacological Basis of Therapeutics</i> , 8th ed. 346-349 (1990).
Examiner	<i>Mark Bern</i>	Date Considered <i>7/6/01</i>

Form PTO 1449

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 8

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub Class	Trans. Yes	Trans. No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB		C. Malgouris et al., "Autoradiographic Distribution of [3H]-Suridone Binding Sites in the Rat Brain," <i>Drug Develop. Res.</i> , 34:336-343 (1995).
MB		A. Doble et al., "The mechanism of action of zopiclone," <i>Eur. Psychiatry</i> , 10 Suppl. 3:117s-128s (1995).
MB		J.M. Stutzmann et al., "Pharmacological Properties and Mechanism of Action of the Cyclopyrrolones," <i>L. Encéphale</i> , XVIII:393-400 (1992).
MB		V. Bertolasi et al., "Stereochemistry of Benzodiazepine Receptor Ligands. Possible Role of C-H...X Interactions in Drug-Receptor Binding and Crystal Structures of CL 218-872, Zopiclone and DMCM," <i>J. Chem. Soc. Perkin Trans.</i> , 2:283-289 (1990).
MB		F. Jamali et al., "Enantioselective Aspects of Drug Action and Disposition: Therapeutic Pitfalls," <i>Journal of Pharmaceutical Sciences</i> , 78(9):695-715 (1989).
MB		A. Verma and S.H. Snyder, "Peripheral Type Benzodiazepine Receptors," <i>Annu. Rev. Pharmacol. Toxicol.</i> , 29:307-322 (1989).
MB		J.P. Brun, "Zopiclone, a Cyclopyrrolone Hypnotic: Review of Properties," <i>Pharmacology, Biochemistry and Behavior</i> , 29:831-832 (1988).
MB		P.A. Borea et al., "Stereochemical Features Controlling Binding and Intrinsic Activity Properties of Benzodiazepine-Receptor Ligands," <i>Molecular Pharmacology</i> , 31:334-344 (1987).

Examiner	<i>Mark Ubel</i>	Date Considered	<i>7/6/01</i>
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>			

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 9

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Country	Class	Sub Class	Trans. Yes	Trans. No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB		K.L. Goa and R.C. Heel, "Zopiclone, a Review of Its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy as an Hypnotic," <i>Drugs</i> , 32(1):48-65 (1986).				
MB		P. Jacqmin and M. Lesne, "Les Benzodiazepines: Aspects Pharmacodynamiques," <i>J. Pharm. Belg.</i> , 40(1):35-54 (1985).				
MB		L. Julou et al., "Pharmacological and Clinical Studies of Cyclopymolones: Zopiclone and Suriclone," <i>Pharmacology, Biochemistry and Behavior</i> , 23:653-659 (1985).				
MB		H. Kusnierczyk, "Antitumor Activity of Optical Isomers of Cyclophosphamide, Ifosfamide and Trofosfamide as Compared to Clinically Used Racemates," <i>J. Immunopharm.</i> , 8(4):455-480 (1986).				
MB		F. Jamali, "Pharmacokinetics of enantiomers of chiral non-steroidal anti-inflammatory drugs," <i>Eur. J. Drug Metab. and Pharmacokin</i> , 12(1):1-9 (1988).				
MB		D.W. Robertson et al., "Absolute Configurations and Pharmacological Activities of the Optical Isomers of Fluoxetine & Selective Serotonin-Uptake Inhibitor," <i>J. Med. Chem.</i> , 31:1412-1417 (1988).				
<table border="1"> <tr> <td>Examiner</td> <td><i>Mark Beal</i></td> <td>Date Considered</td> <td><i>7/6/01</i></td> </tr> </table>			Examiner	<i>Mark Beal</i>	Date Considered	<i>7/6/01</i>
Examiner	<i>Mark Beal</i>	Date Considered	<i>7/6/01</i>			
<p>*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.</p>						

INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)

Page 10

TECH CENTER 160C/2900

JUN 11 2001

RECEIVED

Attorney No. Q62017	Serial No. 09/722,438
Applicant: Claude Cotrel, et al	
Filing Date: November 28, 2000	Group: 1624



U.S. PATENT DOCUMENTS

Examiner Initial*	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

MB	Braestrup C., Squires R.F.. Brain specific benzodiazepine receptors. <i>Brit J Psychiat</i> 1978; 133 : 249-260.
MB	Garzone P., Kroboth P., Pharmacokinetics of the Newer Benzodiazepines, <i>Clinical Pharmacokinetics</i> 16: 337-364 (1989).
MB	Miller L.G., Galpern W.R., Byrnes J.J., and Greenblatt, D.J., Benzodiazepine Receptor Binding of Benzodiazepine Hypnotics: Receptor and Ligand Specificity, <i>Pharmacology Biochem. And Beh.</i> Vol. 43, pp. 413-416, 1992.
MB	Greenblatt D.J., Divoll M., Abernethy D.R., Ochs H.R., and Shader R.I., Clinical Pharmacokinetics of the Newer Benzodiazepines, <i>Clin Pharmacokinetics</i> , 8: 233-252 (1983)
MB	Benavides, J., Peny B., Durand A. et al. Comparative <i>in vivo</i> and <i>in vitro</i> regional selectivity of central ω (benzodiazepine) site ligands in inhibiting [³ H]flumazenil binding in the rat central nervous system. <i>J Pharmacol Exp Therap</i> 1992; 263 : 884-896
MB	Ankier S.I., Goa K.L., Quazepam: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy in Insomnia, <i>Drugs</i> 35: 42-62 (1988).
MB	Gaillot J., Heusse D., Houghton G.W. et al. Pharmacokinetics and metabolism of zopiclone. <i>Int Pharmacopsychiat</i> 1983; 17 (Suppl 2) : 76-91.

Examiner	<i>Mark V. San</i>	Date Considered	<i>7/6/01</i>
----------	--------------------	-----------------	---------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.